Agena Bioscience in the News

Agena Bioscience Announces Molecular Health As The First Interpretation Software Provider For MassARRAY Insights™

19 September 2017

MassARRAY Insights providers will aid in results interpretation San Diego, CA, September 19, 2017– Agena Bioscience, a global provider of molecular genetic solutions and Molecular Health, a leader in cloud-based decision support technology for precision medicine, have entered into a strategic partnership, whereby Molecular Health Guide® (MH Guide) analysis... Read More

Intermountain Precision Genomics Launches Antidepressant PGx Panels Developed on Agena MassARRAY^®

15 September 2017

NEW YORK, Sept 15, 2017 – Intermountain Precision Genomics’ RxMatch Antidepressant Panel, announced last week, is the lab’s first pharmacogenomics test intended to help physicians use DNA to find the right antidepressants to prescribe to patients. It is also the initial step in a strategy to grow beyond precision... Read More

MassARRAY^® System Selected for Illinois State Cystic Fibrosis Screening of Newborns

1 August 2017

San Diego, CA, August 2, 2017– Agena Bioscience has entered into a 3-year agreement with the Illinois Department of Public Health (IDPH) which will deploy Agena’s MassARRAY System for Cystic Fibrosis (CF) testing as part of the state’s newborn screening program. In 2008, the state of Illinois announced the... Read More

Agena Bioscience and Heartgenetics Announce Co-Marketing Alliance

18 July 2017

HEARTDECODE® Software and Assays Designed for Use with the MassARRAY® DX System San Diego, CA, July 18, 2017– Agena Bioscience today announced a co-promotion agreement leveraging its MassARRAY® DX clinical diagnostics technology with HeartGenetics’ CE-IVD marked products for cardiovascular testing. The MassARRAY DX, a CE-IVD marked system, provides a streamlined... Read More

Agena Bioscience and Intermountain Healthcare Announce Research Collaboration to Advance Precision Medicine

12 July 2017

SAN DIEGO, CA, AND SAINT GEORGE, UTAH – Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue... Read More

Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe

29 June 2017

MassARRAY® System with Chip Prep Module receives CE-IVD marking for general in vitro diagnostic use in Europe SAN DIEGO, Calif., June 29, 2017– Agena Bioscience today announced the European launch of the MassARRAY® System with CHIP Prep Module (CPM), marketed as a CE-IVD product under the Directive 98/79/EC for in... Read More

Agena Bioscience Announces Expanded Partnership With Assurex Health

20 June 2017

MassARRAY® System Selected for Assurex Health’s GeneSight Test SAN DIEGO, Calif., June 20, 2017– Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test. The GeneSight Psychotropic test... Read More

Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues

15 March 2017

SAN DIEGO, Calif., March 15, 2017 — Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs)... Read More

Multiplexed Analysis of ALK, ROS1, and RET Rearrangements in Lung Cancer Enabled by the MassARRAY^® System

9 February 2017

SAN DIEGO, Calif., February 9, 2017 – Agena Bioscience today announced a comparative study published in Scientific Reports highlighting the use of its mass spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer. While Fluorescence In Situ Hybridization (FISH) is the gold standard... Read More

Agena Bioscience Names Genelex as Certified Service Provider for Targeted Genetic Analysis

29 August 2016

SAN DIEGO, Calif., August 29, 2016 — Agena Bioscience today announced the successful certification of Genelex as a Certified Service Provider of the MassARRAY® technology. The MassARRAY System is used to identify and validate SNPs, INDELs, CNV’s, translocations, somatic mutations, including rare variants, and methylation profiles across a variety... Read More